Valuation: Adocia

Market Cap 77.48M 89.13M 72.12M 66.21M 125M 8.51B 127M 850M 334M 4.24B 335M 327M 14.2B P/E 2026 *
-723x
P/E 2027 * 5.73x
Enterprise Value 47.64M 54.8M 44.34M 40.71M 76.88M 5.23B 78.07M 523M 205M 2.6B 206M 201M 8.73B EV / Sales 2026 *
18.9x
EV / Sales 2027 * 3.04x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
1 week+3.46%
Current month-4.08%
1 month-4.08%
3 months-18.82%
6 months-37.86%
Current year-37.96%
1 week 3.85
Extreme 3.85
4.04
1 month 3.62
Extreme 3.62
4.47
3 years 3
Extreme 2.995
14.84
5 years 2.72
Extreme 2.725
14.84
10 years 2.72
Extreme 2.725
62.21
Manager TitleAgeSince
Chief Executive Officer 55 2023-05-10
Director of Finance/CFO - 2024-09-22
Chief Tech/Sci/R&D Officer - 2014-11-30
Director TitleAgeSince
Director/Board Member 55 2013-04-18
Chairman 80 2012-02-23
Director/Board Member 58 2013-06-17
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%+5.44%-46.08%-32.10% 90.06M
+2.35%+2.74%+33.41%+79.20% 55.23B
-0.21%-7.38%+25.34%+63.02% 53.75B
-2.44%+1.40%-15.74%-16.80% 23.48B
-2.85%-7.78%-8.09%+346.36% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
+0.79%-1.06%+29.29%-33.32% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
-5.25%-4.23%+46.41%+169.05% 14.07B
+3.41%-6.61%+163.08%+280.43% 13.02B
Average -0.13%-3.44%+26.42%+138.41% 25.94B
Weighted average by Cap. +0.17%-2.75%+28.19%+120.38%

Financials

2026 *2027 *
Net sales 2.52M 2.9M 2.35M 2.15M 4.07M 277M 4.13M 27.66M 10.86M 138M 10.89M 10.65M 462M 35.4M 40.72M 32.95M 30.25M 57.13M 3.89B 58.01M 388M 152M 1.94B 153M 150M 6.49B
Net income -4.32M -4.97M -4.02M -3.69M -6.97M -474M -7.07M -47.37M -18.59M -236M -18.65M -18.24M -791M -44.33M -50.99M -41.26M -37.88M -71.54M -4.87B -72.64M -486M -191M -2.42B -192M -187M -8.13B
Net Debt -29.84M -34.33M -27.78M -25.5M -48.16M -3.28B -48.91M -327M -129M -1.63B -129M -126M -5.47B 30.18M 34.71M 28.09M 25.79M 48.7M 3.31B 49.45M 331M 130M 1.65B 130M 128M 5.53B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
26-07-31 €3.952 -0.90%
26-07-30 €3.988 -0.05%
26-07-29 €3.990 +0.96%
26-07-28 €3.952 +1.39%
26-07-27 €3.898 +2.04%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.960EUR
Average target price
9.700EUR
Spread / Average Target
+144.95%

Quarterly revenue - Rate of surprise